## Carlo A Marra

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3652714/publications.pdf Version: 2024-02-01

		36303	37204
269	11,616	51	96
papers	citations	h-index	g-index
272	272	272	15844
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Knee osteoarthritis and the knowledgeable, trustworthy pharmacist: Patient and pharmacist perceptions of community pharmacyâ€based education and support. Musculoskeletal Care, 2023, 21, 3-15.	1.4	2
2	Identifying New Zealand Public Preferences for Pharmacist Prescribers in Primary Care: A Discrete Choice Experiment. Patient, 2022, 15, 77-92.	2.7	3
3	Feasibility of a randomised controlled trial of two types of written information for people with knee osteoarthritis. Osteoarthritis and Cartilage Open, 2022, 4, 100254.	2.0	9
4	Pharmacists of the future: What determines graduates' desire to engage in patient-centred services?. Research in Social and Administrative Pharmacy, 2021, 17, 545-552.	3.0	5
5	Evaluating New Zealanders' Values for Drug Coverage Decision Making: Trade-Offs between Treatments for Rare and Common Conditions. Pharmacoeconomics, 2021, 39, 109-119.	3.3	3
6	What Are the Preferences of Patients With Rheumatoid Arthritis for Treatment Modification? A Scoping Review. Patient, 2021, 14, 505-532.	2.7	2
7	Identifying Community Pharmacist Preferences For Prescribing Services in Primary Care in New Zealand: A Discrete Choice Experiment. Applied Health Economics and Health Policy, 2021, 19, 253-266.	2.1	4
8	What free services do pharmacists offer? Investigating the provision of unfunded pharmacy services in community pharmacies. Research in Social and Administrative Pharmacy, 2021, 17, 588-594.	3.0	8
9	R <sub>x</sub> IALTA: evaluating the effect of a pharmacist-led intervention on CV risk in patients with chronic inflammatory diseases in a community pharmacy setting: a prospective pre–post intervention study. BMJ Open, 2021, 11, e043612.	1.9	6
10	Identifying perceptions and themed learning outcomes between pharmacy and dentistry students through interprofessional education and collaboration in the dental clinic. Currents in Pharmacy Teaching and Learning, 2021, 13, 843-847.	1.0	1
11	Examining non-medical prescribing trends in New Zealand: 2016–2020. BMC Health Services Research, 2021, 21, 418.	2.2	3
12	Impact of removing prescription charges on health outcomes: protocol for a randomised controlled trial. BMJ Open, 2021, 11, e049261.	1.9	2
13	Are professional pharmacy services being offered for free in pharmacies? A feasibility study exploring the use of a time motion study in New Zealand. Pharmacy Practice, 2021, 19, 2422.	1.5	0
14	Prevalence of joint-specific osteoarthritis and joint pain in British Columbia, Canada. Rheumatology International, 2021, , 1.	3.0	2
15	Characterization of pharmacist-based medication management services in a community pharmacy. Research in Social and Administrative Pharmacy, 2020, 16, 178-182.	3.0	7
16	Socioeconomic status at diagnosis influences the incremental direct medical costs of systemic lupus erythematosus: A longitudinal population-based study. Seminars in Arthritis and Rheumatism, 2020, 50, 77-83.	3.4	8
17	Capturing Adult Patient Preferences Toward Benefits and Risks of Second-Line Antihyperglycemic Medications Used in Type 2 Diabetes: A Discrete Choice Experiment. Canadian Journal of Diabetes, 2020, 44, 6-13.	0.8	10
18	Assessment of inhaler technique among fourth-year pharmacy students: Implications for the use of entrustable professional activities. Currents in Pharmacy Teaching and Learning, 2020, 12, 281-286.	1.0	3

#	Article	IF	CITATIONS
19	Tapering Biologic Therapy for Rheumatoid Arthritis: A Qualitative Study of Patient Perspectives. Patient, 2020, 13, 225-234.	2.7	12
20	Statin use and lung cancer risk in chronic obstructive pulmonary disease patients: a population-based cohort study. Respiratory Research, 2020, 21, 118.	3.6	13
21	Avoiding immortal time bias in observational studies. European Respiratory Journal, 2020, 55, 1902494.	6.7	0
22	Pharmacists' perceptions of their working conditions and the factors influencing this: Results from 5 Canadian provinces. Canadian Pharmacists Journal, 2020, 153, 161-169.	0.8	6
23	Performance Characteristics of Spirometry With Negative Bronchodilator Response and Methacholine Challenge Testing and Implications for Asthma Diagnosis. Chest, 2020, 158, 479-490.	0.8	21
24	Using Best-Worst Choice Methodology in a Survey of Pharmacists Regarding Pharmacy Practice Skills Teaching. American Journal of Pharmaceutical Education, 2020, 84, 848015.	2.1	2
25	Pharmacist prescribing and care improves cardiovascular risk, but is it cost-effective? A cost-effectiveness analysis of the R <sub>x</sub> EACH study. Canadian Pharmacists Journal, 2019, 152, 257-266.	0.8	25
26	Tapering biologic therapy for people with rheumatoid arthritis in remission: A review of patient perspectives and associated clinical evidence. Musculoskeletal Care, 2019, 17, 161-169.	1.4	9
27	Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis. BMJ Open, 2019, 9, e022577.	1.9	144
28	Inhaled corticosteroids and the risk of lung cancer in COPD: a population-based cohort study. European Respiratory Journal, 2019, 53, 1801257.	6.7	46
29	Economic Evaluation of Pharmacists Tackling the Burden of Hypertension in Japan. Hypertension, 2019, 74, e54-e55.	2.7	6
30	Evaluating Canadians' Values for Drug Coverage Decision Making. Value in Health, 2019, 22, 362-369.	0.3	16
31	Excess Productivity Costs of Systemic Lupus Erythematosus, Systemic Sclerosis, and Sjögren's Syndrome: A General Population–Based Study. Arthritis Care and Research, 2019, 71, 142-154.	3.4	11
32	Risk of preterm delivery and small-for-gestational-age births in women with autoimmune disease using biologics before or during pregnancy: a population-based cohort study. Annals of the Rheumatic Diseases, 2018, 77, annrheumdis-2018-213023.	0.9	22
33	Reliability and Validity of Three Versions of the Brief Fear of Negative Evaluation Scale in Patients With Systemic Sclerosis: A Scleroderma Patient entered Intervention Network Cohort Study. Arthritis Care and Research, 2018, 70, 1646-1652.	3.4	8
34	Validation of the Social Appearance Anxiety Scale in Patients With Systemic Sclerosis: A Scleroderma Patientâ€Centered Intervention Network Cohort Study. Arthritis Care and Research, 2018, 70, 1557-1562.	3.4	17
35	Effect of an interactive text-messaging service on patient retention during the first year of HIV care in Kenya (WelTel Retain): an open-label, randomised parallel-group study. Lancet Public Health, The, 2018, 3, e143-e152.	10.0	54
36	A philosophical framework for pharmacy in the 21st century guided by ethical principles. Research in Social and Administrative Pharmacy, 2018, 14, 309-316.	3.0	21

#	Article	IF	CITATIONS
37	Practical strategies and perceptions from community pharmacists following their experiences with conducting pharmacy practice research: a qualitative content analysis. International Journal of Pharmacy Practice, 2018, 26, 302-309.	0.6	7
38	Exploring strategies to support medication adherence in patients with inflammatory arthritis: a patient-oriented qualitative study using an interactive focus group activity. Patient Preference and Adherence, 2018, Volume 12, 2015-2025.	1.8	8
39	How do parents and providers trade-off between disability and survival? Preferences in the treatment of pediatric medulloblastoma. Patient Preference and Adherence, 2018, Volume 12, 2103-2110.	1.8	1
40	Incremental direct medical costs of systemic lupus erythematosus patients in the years preceding diagnosis: A general population-based study. Lupus, 2018, 27, 1247-1258.	1.6	10
41	Adaptation of POCT for pharmacies to reduce risk and optimize access to care in HIV, the APPROACH study protocol: examining acceptability and feasibility. Pilot and Feasibility Studies, 2018, 4, 59.	1.2	4
42	The Scleroderma Patient-Centered Intervention Network Cohort: baseline clinical features and comparison with other large scleroderma cohorts. Rheumatology, 2018, 57, 1623-1631.	1.9	53
43	Perspectives of Patients with Multiple Sclerosis on Drug Treatment. International Journal of MS Care, 2018, 20, 269-277.	1.0	14
44	Preferences for â€~New' Treatments Diminish in the Face of Ambiguity. Health Economics (United) Tj ETQq0 (	0 9. <sub>19</sub> BT /C	Overlock 10 <sup>-</sup>

45	Validation of the Body Concealment Scale for Scleroderma (BCSS): Replication in the Scleroderma Patient-centered Intervention Network (SPIN) Cohort. Body Image, 2017, 20, 99-106.	4.3	3
46	Tuberculosis testing for healthcare workers in South Africa: A health service analysis using Porter's Five Forces Framework. International Journal of Healthcare Management, 2017, 10, 49-56.	2.0	4
47	Opinions and preferences of British Columbia pharmacists and physicians on medication management services. Canadian Pharmacists Journal, 2017, 150, 42-51.	0.8	2
48	Practice guidelines for pharmacists: The management of osteoarthritis. Canadian Pharmacists Journal, 2017, 150, 156-168.	0.8	14
49	Testing the External Validity of a Discrete Choice Experiment Method: An Application to Latent Tuberculosis Infection Treatment. Value in Health, 2017, 20, 969-975.	0.3	22
50	OMERACT Quality-adjusted Life-years (QALY) Working Group: Do Current QALY Measures Capture What Matters to Patients?. Journal of Rheumatology, 2017, 44, 1899-1903.	2.0	12
51	Societal preferences in the treatment of pediatric medulloblastoma: Balancing risk of death and quality of life. Pediatric Blood and Cancer, 2017, 64, e26340.	1.5	4
52	Do inhaled corticosteroids protect against lung cancer in patients with COPD? A systematic review. Respirology, 2017, 22, 61-70.	2.3	25
53	Economic evaluation of mobile phone text message interventions to improve adherence to HIV therapy in Kenya. Medicine (United States), 2017, 96, e6078.	1.0	31
54	Productivity Losses and Costs in the Less-Common Systemic Autoimmune Rheumatic Diseases. Current Rheumatology Reports, 2017, 19, 72.	4.7	8

#	Article	IF	CITATIONS
55	Filling the gaps in SARDs research: collection and linkage of administrative health data and self-reported survey data for a general population-based cohort of individuals with and without diagnoses of systemic autoimmune rheumatic disease (SARDs) from British Columbia, Canada. BMJ Open, 2017, 7, e013977.	1.9	8
56	Consumer preferences for food allergen labeling. Allergy, Asthma and Clinical Immunology, 2017, 13, 19.	2.0	23
57	Ten-year trends in direct costs of asthma: a population-based study. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 291-299.	5.7	16
58	The validity of the SF-12 and SF-6D instruments in people living with HIV/AIDS in Kenya. Health and Quality of Life Outcomes, 2017, 15, 143.	2.4	20
59	Cost-effectiveness of pharmacist care for managing hypertension in Canada. Canadian Pharmacists Journal, 2017, 150, 184-197.	0.8	59
60	The Effect of Smartphone Interventions on Patients With Chronic Obstructive Pulmonary Disease Exacerbations: Systematic Review and Meta-Analysis. Iproceedings, 2017, 3, e6.	0.1	0
61	Cost-Effectiveness of Bronchial Thermoplasty, Omalizumab, and Standard Therapy for Moderate-to-Severe Allergic Asthma. PLoS ONE, 2016, 11, e0146003.	2.5	56
62	Validation of the Selfâ€Efficacy for Managing Chronic Disease Scale: A Scleroderma Patientâ€Centered Intervention Network Cohort Study. Arthritis Care and Research, 2016, 68, 1195-1200.	3.4	31
63	Excess medical costs in patients with asthma and the role of comorbidity. European Respiratory Journal, 2016, 48, 1584-1592.	6.7	33
64	Effectiveness of a pharmacist-driven intervention in COPD (EPIC): study protocol for a randomized controlled trial. Trials, 2016, 17, 502.	1.6	17
65	Health State Utilities and Disease Duration in Systemic Sclerosis: Is There an Association?. Journal of Rheumatology, 2016, 43, 1832-1837.	2.0	3
66	Using Optimal Test Assembly Methods for Shortening Patientâ€Reported Outcome Measures: Development and Validation of the Cochin Hand Function Scaleâ€6: A Scleroderma Patientâ€Centered Intervention Network Cohort Study. Arthritis Care and Research, 2016, 68, 1704-1713.	3.4	23
67	The Impact of Price-cap Regulations on Exit by Generic Pharmaceutical Firms. Medical Care, 2016, 54, 884-890.	2.4	17
68	Quantitative analysis of multiple sclerosis patients' preferences for drug treatment: a best–worst scaling study. Therapeutic Advances in Neurological Disorders, 2016, 9, 287-296.	3.5	29
69	Cognitive status is a determinant of health resource utilization among individuals with a history of falls: a 12-month prospective cohort study. Osteoporosis International, 2016, 27, 943-951.	3.1	9
70	Factors associated with pharmacists' perceptions of their working conditions and safety and effectiveness of patient care. Canadian Pharmacists Journal, 2016, 149, 18-27.	0.8	34
71	Does Introducing Imprecision around Probabilities for Benefit and Harm Influence the Way People Value Treatments?. Medical Decision Making, 2016, 36, 490-502.	2.4	24
72	Populationâ€based evaluation of the effectiveness of two regimens for emergency contraception. International Journal of Gynecology and Obstetrics, 2016, 133, 342-346.	2.3	5

#	Article	IF	CITATIONS
73	The natural history of severe asthma and influences of early risk factors: a population-based cohort study. Thorax, 2016, 71, 267-275.	5.6	45
74	Identifying relationships between the professional culture of pharmacy, pharmacists' personality traits, and the provision of advanced pharmacy services. Research in Social and Administrative Pharmacy, 2016, 12, 56-67.	3.0	38
75	Are patients willing to pay for total shoulder arthroplasty? Evidence from a discrete choice experiment. Canadian Journal of Surgery, 2016, 59, 107-112.	1.2	14
76	The Effect of Smartphone Interventions on Patients With Chronic Obstructive Pulmonary Disease Exacerbations: A Systematic Review and Meta-Analysis. JMIR MHealth and UHealth, 2016, 4, e105.	3.7	63
77	Impact of allowing pharmacists to independently renew prescriptions: A population-based study. Journal of the American Pharmacists Association: JAPhA, 2015, 55, 398-404.	1.5	8
78	Healthcare Worker Preferences for Active Tuberculosis Case Finding Programs in South Africa: A Best-Worst Scaling Choice Experiment. PLoS ONE, 2015, 10, e0133304.	2.5	15
79	Group Medical Visits (GMVs) in primary care: an RCT of group-based versus individual appointments to reduce HbA1c in older people: Figure1. BMJ Open, 2015, 5, e007441.	1.9	8
80	BC Medication Management Project. Canadian Pharmacists Journal, 2015, 148, 90-100.	0.8	13
81	Ten-Year Trends in Direct Costs of COPD. Chest, 2015, 148, 640-646.	0.8	66
82	Challenges in Measuring the Societal Value of Orphan Drugs: Insights from a Canadian Stated Preference Survey. Patient, 2015, 8, 93-101.	2.7	22
83	Exploring the Potential Cost-Effectiveness of Patient Decision Aids for Use in Adults with Obstructive Sleep Apnea. Medical Decision Making, 2015, 35, 671-682.	2.4	9
84	Action Seniors! - secondary falls prevention in community-dwelling senior fallers: study protocol for a randomized controlled trial. Trials, 2015, 16, 144.	1.6	27
85	Health economic evaluation of plasma oxysterol screening in the diagnosis of Niemann–Pick Type C disease among intellectually disabled using discrete event simulation. Molecular Genetics and Metabolism, 2015, 114, 226-232.	1.1	11
86	Perceptions of British Columbia residents and their willingness to pay for medication management services provided by pharmacists. Canadian Pharmacists Journal, 2015, 148, 263-273.	0.8	15
87	The added effect of comorbidity on health-related quality of life in patients with asthma. Quality of Life Research, 2015, 24, 2507-2517.	3.1	26
88	Challenges with cost-utility analyses of behavioural interventions among older adults at risk for dementia. British Journal of Sports Medicine, 2015, 49, 1343-1347.	6.7	15
89	Societal preferences for rheumatoid arthritis treatments: evidence from a discrete choice experiment. Rheumatology, 2015, 54, 1816-1825.	1.9	35
90	Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis. Diabetologia, 2015, 58, 493-504.	6.3	140

#	Article	IF	CITATIONS
91	Canadian Policy on Food Allergen Labelling: Consumers' Perspectives Regarding Unmet Needs. Universal Journal of Public Health, 2015, 3, 41-48.	0.1	6
92	Deâ€escalation of therapy for pediatric medulloblastoma: Tradeâ€offs between quality of life and survival. Pediatric Blood and Cancer, 2014, 61, 1300-1304.	1.5	21
93	Costâ€Utility Analysis of a Multidisciplinary Strategy to Manage Osteoarthritis of the Knee: Economic Evaluation of a Cluster Randomized Controlled Trial Study. Arthritis Care and Research, 2014, 66, 810-816.	3.4	21
94	Dispensation of long-acting  agonists with or without inhaled corticosteroids, and risk of asthma-related hospitalisation: a population-based study. Thorax, 2014, 69, 328-334.	5.6	16
95	Empowering pharmacists in asthma management through interactive SMS (EmPhAsIS): study protocol for a randomized controlled trial. Trials, 2014, 15, 488.	1.6	15
96	Diagnostic Strategies Incorporating Computed Tomography Angiography for Pulmonary Embolism. Journal of Thoracic Imaging, 2014, 29, 209-216.	1.5	16
97	Pharmacy-based Immunization in Rural Communities Strategy (PhICS). Canadian Pharmacists Journal, 2014, 147, 33-44.	0.8	28
98	Community pharmacist surveillance of hypertension in pregnancy. Canadian Pharmacists Journal, 2014, 147, 307-315.	0.8	2
99	Cost–effectiveness of abatacept for moderate-to-severe rheumatoid arthritis. Expert Review of Pharmacoeconomics and Outcomes Research, 2014, 14, 9-18.	1.4	1
100	"Employment and arthritis: making it work―a randomized controlled trial evaluating an online program to help people with inflammatory arthritis maintain employment (study protocol). BMC Medical Informatics and Decision Making, 2014, 14, 59.	3.0	12
101	Network vs. Pairwise Meta-Analyses: A Case Study of the Impact of an Evidence-Synthesis Paradigm on Value of Information Outcomes. Pharmacoeconomics, 2014, 32, 995-1004.	3.3	10
102	Incorporating external evidence in trial-based cost-effectiveness analyses: the use of resampling methods. Trials, 2014, 15, 201.	1.6	5
103	Determinants Of Quality Of Life In Newly Diagnosed Hiv Infected Patients In Kenya. Value in Health, 2014, 17, A280.	0.3	1
104	Patient preferences and experiences of CPAP and oral appliances for the treatment of obstructive sleep apnea: a qualitative analysis. Sleep and Breathing, 2013, 17, 659-666.	1.7	77
105	A Quantitative Benefit-Risk Analysis of Isoniazid for Treatment of Latent Tuberculosis Infection Using Incremental Benefit Framework. Value in Health, 2013, 16, 66-75.	0.3	9
106	Need for Speed: An Efficient Algorithm for Calculation of Single-Parameter Expected Value of Partial Perfect Information. Value in Health, 2013, 16, 438-448.	0.3	27
107	Genomic testing to determine drug response: measuring preferences of the public and patients using Discrete Choice Experiment (DCE). BMC Health Services Research, 2013, 13, 454.	2.2	28
108	Barriers for integrating personalized medicine into clinical practice: A qualitative analysis. American Journal of Medical Genetics, Part A, 2013, 161, 758-763.	1.2	31

#	Article	IF	CITATIONS
109	A Metaâ€analysis of intradermal versus intramuscular influenza vaccines: Immunogenicity and Adverse Events. Influenza and Other Respiratory Viruses, 2013, 7, 584-603.	3.4	52
110	Comparative outcomes of leukotriene receptor antagonists and long-acting β-agonists as add-on therapy in asthmatic patients: A population-based study. Journal of Allergy and Clinical Immunology, 2013, 132, 63-69.	2.9	19
111	Comparison of HRQL Between Unicompartmental Knee Arthroplasty and Total Knee Arthroplasty for the Treatment of Osteoarthritis. Journal of Arthroplasty, 2013, 28, 187-190.	3.1	43
112	Authors' Response to "Comparative Effectiveness and Personalized Medicine―by Dr. J.C. Hornberger. Value in Health, 2013, 16, 697.	0.3	0
113	TWO‣EVEL RESAMPLING AS A NOVEL METHOD FOR THE CALCULATION OF THE EXPECTED VALUE OF SAMPLE INFORMATION IN ECONOMIC TRIALS. Health Economics (United Kingdom), 2013, 22, 877-882.	1.7	8
114	An Economic Evaluation of Resistance Training and Aerobic Training versus Balance and Toning Exercises in Older Adults with Mild Cognitive Impairment. PLoS ONE, 2013, 8, e63031.	2.5	43
115	Detection Bias and Overestimation of Bladder Cancer Risk in Type 2 Diabetes: A matched cohort study. Diabetes Care, 2013, 36, 3070-3075.	8.6	26
116	Responsiveness of Health State Utility Values in Knee Osteoarthritis. Journal of Rheumatology, 2013, 40, 2075-2082.	2.0	3
117	The effect of weekly short message service communication on patient retention in care in the first year after HIV diagnosis: study protocol for a randomised controlled trial (WelTel Retain). BMJ Open, 2013, 3, e003155.	1.9	40
118	Costs and Health Outcomes Associated With Primary vs Secondary Care After an Asthma-Related Hospitalization. Chest, 2013, 144, 428-435.	0.8	16
119	Risk of Gastrointestinal Events in Patients with Rheumatoid Arthritis After Withdrawal of Rofecoxib. Journal of Rheumatology, 2012, 39, 910-915.	2.0	4
120	Is Surgical Fixation for Stress-Positive Unstable Ankle Fractures Cost Effective? Results of a Multicenter Randomized Control Trial. Journal of Orthopaedic Trauma, 2012, 26, 652-658.	1.4	27
121	Pharmacistâ€initiated intervention trial in osteoarthritis: A multidisciplinary intervention for knee osteoarthritis. Arthritis Care and Research, 2012, 64, 1837-1845.	3.4	51
122	Cost-Effectiveness of Using a Molecular Diagnostic Test to Improve Preoperative Diagnosis of Thyroid Cancer. Value in Health, 2012, 15, 1005-1013.	0.3	30
123	The "Lost NNT―can be used to represent uncertainty surrounding number needed to treat. Journal of Clinical Epidemiology, 2012, 65, 863-868.	5.0	1
124	The Cost Effectiveness of Human Papillomavirus Vaccines. Drugs, 2012, 72, 715-743.	10.9	67
125	Barriers to integrating personalized medicine into clinical practice: a best–worst scaling choice experiment. Genetics in Medicine, 2012, 14, 520-526.	2.4	34
126	The issue of comparators in economic evaluations of biologic response modifiers in rheumatoid arthritis. Best Practice and Research in Clinical Rheumatology, 2012, 26, 659-676.	3.3	9

#	Article	IF	CITATIONS
127	Economic and Humanistic Burden of External Genital Warts. Pharmacoeconomics, 2012, 30, 1-16.	3.3	34
128	Future Impact of Various Interventions on the Burden of COPD in Canada: A Dynamic Population Model. PLoS ONE, 2012, 7, e46746.	2.5	32
129	Trends in Asthma-Related Direct Medical Costs from 2002 to 2007 in British Columbia, Canada: A Population Based-Cohort Study. PLoS ONE, 2012, 7, e50949.	2.5	59
130	Evaluating the Labour Costs Associated with Pharmacy Adaptation Services in British Columbia. Canadian Pharmacists Journal, 2012, 145, 78-82.	0.8	6
131	Safety Of Long-Acting Beta Agonists (LABA) With Or Without Inhaled Corticosteroids In Asthma. , 2012, , .		0
132	The cost of fall related presentations to the ED: A prospective, in-person, patient-tracking analysis of health resource utilization. Osteoporosis International, 2012, 23, 1513-1519.	3.1	24
133	SF-6D and EQ-5D result in widely divergent incremental cost-effectiveness ratios in a clinical trial of older women: implications for health policy decisions. Osteoporosis International, 2012, 23, 1849-1857.	3.1	23
134	In-Depth Analysis of Patient-Clinician Cell Phone Communication during the WelTel Kenya1 Antiretroviral Adherence Trial. PLoS ONE, 2012, 7, e46033.	2.5	46
135	Patient Preference for Latent Tuberculosis Infection Preventive Treatment: A Discrete Choice Experiment. Value in Health, 2011, 14, 937-943.	0.3	26
136	Comparison of pregnancy rates after two hormonal emergency contraceptives. Contraception, 2011, 84, 333-334.	1.5	0
137	Family Physicians' Perceptions of Pharmacy Adaptation Services in British Columbia. Canadian Pharmacists Journal, 2011, 144, 172-178.	0.8	7
138	The Demise of Portable Monitoring to Diagnose OSA? Not So Fast!. Sleep, 2011, 34, 691-692.	1.1	7
139	Is the delay in diagnosis of pulmonary tuberculosis related to exposure to fluoroquinolones or any antibiotic?. International Journal of Tuberculosis and Lung Disease, 2011, 15, 1062-1068.	1.2	27
140	Pharmacy Owner and Manager Perceptions of Pharmacy Adaptation Services in British Columbia. Canadian Pharmacists Journal, 2011, 144, 231-235.	0.8	5
141	Sustained Economic Benefits of Resistance Training in Communityâ€Dwelling Senior Women. Journal of the American Geriatrics Society, 2011, 59, 1232-1237.	2.6	11
142	Introduction to economic modeling for clinical rheumatologists: application to biologic agents in rheumatoid arthritis. Clinical Rheumatology, 2011, 30, 9-18.	2.2	20
143	Time-varying incidence of cancer after the onset of type 2 diabetes: evidence of potential detection bias. Diabetologia, 2011, 54, 2263-2271.	6.3	135
144	Economic evaluation of dose–response resistance training in older women: a cost-effectiveness and cost-utility analysis. Osteoporosis International, 2011, 22, 1355-1366.	3.1	33

1

#	Article	IF	CITATIONS
145	Antibiotic consumption in children prior to diagnosis of asthma. BMC Pulmonary Medicine, 2011, 11, 32.	2.0	14
146	Agreement between aggregate and individual-level measures of income and education: a comparison across three patient groups. BMC Health Services Research, 2011, 11, 69.	2.2	34
147	Evaluating societal preferences for human papillomavirus vaccine and cervical smear test screening programme. Sexually Transmitted Infections, 2011, 87, 52-57.	1.9	37
148	Risk of Breast Cancer After Onset of Type 2 Diabetes. Diabetes Care, 2011, 34, 2542-2544.	8.6	41
149	Randomized Controlled Trial Evaluating Pictogram Augmentation of HIV Medication Information. Annals of Pharmacotherapy, 2011, 45, 1378-1383.	1.9	22
150	Falls-related self-efficacy is independently associated with quality-adjusted life years in older women. Age and Ageing, 2011, 40, 340-346.	1.6	21
151	Valuing Health for Clinical and Economic Decisions: Directions Relevant for Rheumatologists. Journal of Rheumatology, 2011, 38, 1770-1775.	2.0	13
152	Value for Money? Array Genomic Hybridization for Diagnostic Testing for Genetic Causes of Intellectual Disability. American Journal of Human Genetics, 2010, 86, 765-772.	6.2	56
153	International comparison of cost of falls in older adults living in the community: a systematic review. Osteoporosis International, 2010, 21, 1295-1306.	3.1	236
154	Effects of prescription adaptation by pharmacists. BMC Health Services Research, 2010, 10, 313.	2.2	14
155	Responses to Comments of Weis. Health and Quality of Life Outcomes, 2010, 8, 6.	2.4	4
156	After patients are diagnosed with knee osteoarthritis, what do they do?. Arthritis Care and Research, 2010, 62, 510-515.	3.4	27
157	The independent contribution of executive functions to health related quality of life in older women. BMC Geriatrics, 2010, 10, 16.	2.7	128
158	A quantitative evaluation of the regulatory assessment of the benefits and risks of rofecoxib relative to naproxen: an application of the incremental netâ€benefit framework. Pharmacoepidemiology and Drug Safety, 2010, 19, 1172-1180.	1.9	12
159	Cost-Effectiveness of the Addition of Rituximab to CHOP Chemotherapy in First-Line Treatment for Diffuse Large B-Cell Lymphoma in a Population-Based Observational Cohort in British Columbia, Canada. Value in Health, 2010, 13, 703-711.	0.3	25
160	An Ounce of Prevention Is Worth a Pound of Cure: A Cost-Effectiveness Analysis of Incidentally Detected Aneurysms in Functional MRI Research. Value in Health, 2010, 13, 761-769.	0.3	10
161	Exploring patients' perceptions for insulin therapy in type 2 diabetes: a Brazilian and Canadian qualitative study. Patient Preference and Adherence, 2010, 4, 171.	1.8	13

162 Use Of Antibiotics Delays Diagnosis Of Tuberculosis. , 2010, , .

#	Article	IF	CITATIONS
163	Assessing Pharmacists' Attitudes regarding Delivery of the Pandemic Influenza Vaccine in British Columbia. Canadian Pharmacists Journal, 2010, 143, 278-284.	0.8	8
164	A discrete choice experiment evaluation of patients' preferences for different risk, benefit, and delivery attributes of insulin therapy for diabetes management. Patient Preference and Adherence, 2010, 4, 433.	1.8	32
165	Direct Health Care Costs Associated with Asthma in British Columbia. Canadian Respiratory Journal, 2010, 17, 74-80.	1.6	122
166	A systematic review of economic evaluations of therapy in asthma. Journal of Asthma and Allergy, 2010, 3, 33.	3.4	22
167	Preference-Based Quality of Life of End-Stage Ankle Arthritis Treated with Arthroplasty or Arthrodesis. Foot and Ankle International, 2010, 31, 563-566.	2.3	57
168	Independent and inverse association of healthcare utilisation with physical activity in older adults with multiple chronic conditions. British Journal of Sports Medicine, 2010, 44, 1024-1028.	6.7	26
169	Impact of adverse drug reaction and predictivity of quality of life status in tuberculosis. European Respiratory Journal, 2010, 36, 206-208.	6.7	20
170	Does physical activity reduce seniors' need for healthcare?: a study of 24 281 Canadians. British Journal of Sports Medicine, 2010, 44, 902-904.	6.7	41
171	Pharmacists' Preferences for Providing Patient-Centered Services: A Discrete Choice Experiment to Guide Health Policy. Annals of Pharmacotherapy, 2010, 44, 1554-1564.	1.9	27
172	Sustained Cognitive and Economic Benefits of Resistance Training Among Community- Dwelling Senior Women: A 1-Year Follow-up Study of the Brain Power Study. Archives of Internal Medicine, 2010, 170, 2036.	3.8	24
173	A statistical method was used for the meta-analysis of tests for latent TBÂin the absence of a gold standard, combining random-effect andÂlatent-class methods to estimate test accuracy. Journal of Clinical Epidemiology, 2010, 63, 257-269.	5.0	36
174	Effects of a mobile phone short message service on antiretroviral treatment adherence in Kenya (WelTel Kenya1): a randomised trial. Lancet, The, 2010, 376, 1838-1845.	13.7	1,098
175	Does a home-based strength and balance programme in people aged >=80 years provide the best value for money to prevent falls? A systematic review of economic evaluations of falls prevention interventions. British Journal of Sports Medicine, 2010, 44, 80-89.	6.7	156
176	Antibiotic Use in Children Is Associated With Increased Risk of Asthma. Pediatrics, 2009, 123, 1003-1010.	2.1	244
177	Socioeconomic Differences in Preferences and Willingness-to-Pay for Insulin Delivery Systems in Type 1 and Type 2 Diabetes. Diabetes Technology and Therapeutics, 2009, 11, 567-573.	4.4	27
178	A valuation of patients' willingness-to-pay for insulin delivery in diabetes. International Journal of Technology Assessment in Health Care, 2009, 25, 359-366.	0.5	34
179	Pharmacists' Perspectives on Providing Chronic Disease Management Services in the Community — Part I: Current Practice Environment. Canadian Pharmacists Journal, 2009, 142, 234-239.	0.8	11
180	Pharmacists' Perspectives on Providing Chronic Disease Management Services in the Community — Part II: Development and Implementation of Services. Canadian Pharmacists Journal, 2009, 142, 284-288.e1.	0.8	11

#	Article	IF	CITATIONS
181	Meta-analysis of the Impact of 9 Medication Classes on Falls in Elderly Persons. Archives of Internal Medicine, 2009, 169, 1952.	3.8	1,016
182	The economics of treatment in early rheumatoid arthritis. Best Practice and Research in Clinical Rheumatology, 2009, 23, 83-92.	3.3	17
183	Parental perceived value of a diagnosis for intellectual disability (ID): A qualitative comparison of families with and without a diagnosis for their child's ID. American Journal of Medical Genetics, Part A, 2009, 149A, 2393-2402.	1.2	69
184	Now that we know what's BeSt, what is good value for the money?. Arthritis and Rheumatism, 2009, 61, 289-290.	6.7	4
185	Cost-effectiveness of oral appliances in the treatment of obstructive sleep apnoea–hypopnoea. Sleep and Breathing, 2009, 13, 241-252.	1.7	36
186	Economic burden of asthma: a systematic review. BMC Pulmonary Medicine, 2009, 9, 24.	2.0	580
187	Valuing the benefit of diagnostic testing for genetic causes of idiopathic developmental disability: willingness to pay from families of affected children. Clinical Genetics, 2009, 75, 514-521.	2.0	53
188	Bayesian and classical estimation of mixed logit: An application to genetic testing. Journal of Health Economics, 2009, 28, 598-610.	2.7	61
189	Measuring health-related quality of life in tuberculosis: a systematic review. Health and Quality of Life Outcomes, 2009, 7, 14.	2.4	125
190	Effectiveness and Cost Effectiveness of Human Papillomavirus Vaccine. Pharmacoeconomics, 2009, 27, 127-147.	3.3	82
191	Cost Effectiveness of Herpes Zoster Vaccine in Canada. Pharmacoeconomics, 2009, 27, 991-1004.	3.3	48
192	Treatment of Very Early Rheumatoid Arthritis With Symptomatic Therapy, Disease-Modifying Antirheumatic Drugs, or Biologic Agents. Annals of Internal Medicine, 2009, 151, 612.	3.9	86
193	Patients With Genital Warts Have a Decreased Quality of Life. Sexually Transmitted Diseases, 2009, 36, 258-260.	1.7	19
194	The challenge of making cost-effective asthma therapy available. International Journal of Tuberculosis and Lung Disease, 2009, 13, 545.	1.2	0
195	The validity of generic and condition-specific preference-based instruments: the ability to discriminate asthma control status. Quality of Life Research, 2008, 17, 453-462.	3.1	64
196	The Economic Impact of Obstructive Sleep Apnea. Lung, 2008, 186, 7-12.	3.3	214
197	Health state utility values: A description of their development and application for rheumatic diseases. Arthritis and Rheumatism, 2008, 59, 1018-1026.	6.7	24
198	Cost-Effectiveness of LTBI Treatment for TB Contacts in British Columbia. Value in Health, 2008, 11, 842-852.	0.3	15

#	Article	IF	CITATIONS
199	Health State Utilities in Latent and Active Tuberculosis. Value in Health, 2008, 11, 1154-1161.	0.3	62
200	Reliability studies of diagnostic tests are not using enough observers for robust estimation of interobserver agreement: a simulation study. Journal of Clinical Epidemiology, 2008, 61, 722-727.	5.0	15
201	Letter to the Editor. Vaccine, 2008, 26, 5244.	3.8	1
202	Technical Note: Acceptability Curves Could Be Misleading When Correlated Strategies Are Compared. Medical Decision Making, 2008, 28, 306-307.	2.4	6
203	Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax, 2008, 63, 962-967.	5.6	47
204	Epidemiology and costs associated with genital warts in Canada. Sexually Transmitted Infections, 2008, 85, 111-115.	1.9	58
205	Health-Related Quality of Life Trajectories Among Adults With Tuberculosis. Chest, 2008, 133, 396-403.	0.8	70
206	Cost-Effectiveness of Continuous Positive Airway Pressure Therapy in Patients with Obstructive Sleep Apnea-Hypopnea in British Columbia. Canadian Respiratory Journal, 2008, 15, 159-165.	1.6	41
207	Design of a randomized trial of a multidisciplinary intervention for knee osteoarthritis: Pharmacist Initiated Intervention Trial in Osteoarthritis (PhIT-OA). Canadian Pharmacists Journal, 2008, 141, 33-38.	0.8	4
208	Patient reported outcomes for rheumatoid arthritis: where are we and where are we going?. Journal of Rheumatology, 2008, 35, 1482-3.	2.0	5
209	Short-term influence of adalimumab on work productivity outcomes in patients with rheumatoid arthritis. Journal of Rheumatology, 2008, 35, 1729-36.	2.0	21
210	Self-managed oral anticoagulation therapy. Cmaj, 2007, 176, 813-814.	2.0	0
211	Economic evaluations of anticoagulants for the prophylaxis of venous thromboembolism following major trauma. Expert Review of Pharmacoeconomics and Outcomes Research, 2007, 7, 403-413.	1.4	0
212	Evolution of Clinical Pharmacy in the Practice of Rheumatology. Annals of Pharmacotherapy, 2007, 41, 1705-1707.	1.9	1
213	Cost–effectiveness of tumor necrosis factor-α antagonists in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Expert Review of Pharmacoeconomics and Outcomes Research, 2007, 7, 155-169.	1.4	4
214	The impact of obstructive sleep apnea and daytime sleepiness on work limitation. Sleep Medicine, 2007, 9, 42-53.	1.6	191
215	Not all "quality-adjusted life years―are equal. Journal of Clinical Epidemiology, 2007, 60, 616-624.	5.0	89
216	Physical activity as a mediator of the impact of chronic conditions on quality of life in older adults. Health and Quality of Life Outcomes, 2007, 5, 68.	2.4	92

#	Article	IF	CITATIONS
217	Using the health assessment questionnaire to estimate preferenceâ€based single indices in patients with rheumatoid arthritis. Arthritis and Rheumatism, 2007, 57, 963-971.	6.7	68
218	Improving osteoarthritis detection in the community: Pharmacist identification of new, diagnostically confirmed osteoarthritis. Arthritis and Rheumatism, 2007, 57, 1238-1244.	6.7	41
219	Abatacept: A Novel Treatment for Moderate-to-Severe Rheumatoid Arthritis. Pharmacotherapy, 2007, 27, 1693-1701.	2.6	15
220	Considerations and preliminary proposals for defining a reference case for economic evaluations in ankylosing spondylitis. Journal of Rheumatology, 2007, 34, 1178-83.	2.0	6
221	Do visual analogue scale (VAS) derived standard gamble (SG) utilities agree with Health Utilities Index utilities? A comparison of patient and community preferences for health status in rheumatoid arthritis patients. Health and Quality of Life Outcomes, 2006, 4, 25.	2.4	28
222	The Cost of Sleep Disorders: No Snoring Matter. Sleep, 2006, 29, 282-283.	1.1	7
223	In Reply: Antibiotic Use During the First Year of Life and Asthma. Chest, 2006, 130, 1624-1625.	0.8	2
224	Interferon-Based Combination Anti-Viral Therapy for Hepatitis C Virus After Liver Transplantation: A Review and Quantitative Analysis American Journal of Transplantation, 2006, 6, 1586-1599.	4.7	179
225	Approval process and access to prescription drugs in Canada. Arthritis and Rheumatism, 2006, 55, 9-11.	6.7	8
226	Health economic evaluation: A primer for the practicing rheumatologist. Arthritis and Rheumatism, 2006, 55, 648-656.	6.7	15
227	Does Antibiotic Exposure During Infancy Lead to Development of Asthma?. Chest, 2006, 129, 610-618.	0.8	185
228	Cost-effectiveness of Continuous Positive Airway Pressure Therapy for Moderate to Severe Obstructive Sleep Apnea/Hypopnea. Archives of Internal Medicine, 2006, 166, 977.	3.8	131
229	Improving rheumatoid arthritis outcomes: How do we get there?. American Journal of Health-System Pharmacy, 2006, 63, S42-S44.	1.0	0
230	Cost-effectiveness of self-managed versus physician-managed oral anticoagulation therapy. Cmaj, 2006, 174, 1847-1852.	2.0	68
231	Rheumatoid arthritis: A primer for pharmacists. American Journal of Health-System Pharmacy, 2006, 63, S4-S10.	1.0	7
232	Levofloxacin Treatment of Active Tuberculosis and the Risk of Adverse Events. Chest, 2005, 128, 1406-1413.	0.8	28
233	A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis. Social Science and Medicine, 2005, 60, 1571-1582.	3.8	333
234	Willingness to pay to assess patient preferences for therapy in a Canadian setting. BMC Health Services Research, 2005, 5, 43.	2.2	47

#	Article	IF	CITATIONS
235	Are indirect utility measures reliable and responsive in rheumatoid arthritis patients?. Quality of Life Research, 2005, 14, 1333-1344.	3.1	72
236	Continuous Positive Airway Pressure Therapy for Obstructive Sleep Apnea Syndrome: Do the Dollars Make Sense?. Sleep, 2005, 28, 1211-1213.	1.1	13
237	When patients have to pay a share of drug costs: effects on frequency of physician visits, hospital admissions and filling of prescriptions. Cmaj, 2005, 173, 1335-1340.	2.0	56
238	Evaluating Health-Related Quality-of-Life Studies in Paediatric Populations. Pharmacoeconomics, 2005, 23, 659-685.	3.3	209
239	An Overview of Economic Evaluations for Drugs Used in Rheumatoid Arthritis. Drugs, 2005, 65, 473-496.	10.9	65
240	The impact of low family income on self-reported health outcomes in patients with rheumatoid arthritis within a publicly funded health-care environment â€â€ Presented in part as a poster at the International Society of Quality of Life Research Annual Meeting in Prague, Czech Republic, November 2003 Rheumatology, 2004, 43, 1390-1397.	1.9	52
241	An Economic Model of 2-Hour Post-Dose Ciclosporin Monitoring in Renal Transplantation. Pharmacoeconomics, 2004, 22, 621-632.	3.3	8
242	An assessment of quality of sleep and the use of drugs with sedating properties in hospitalized adult patients. Health and Quality of Life Outcomes, 2004, 2, 17.	2.4	67
243	Factors influencing quality of life in patients with active tuberculosis. Health and Quality of Life Outcomes, 2004, 2, 58.	2.4	76
244	A Comparison of Four Indirect Methods of Assessing Utility Values in Rheumatoid Arthritis. Medical Care, 2004, 42, 1125-1131.	2.4	114
245	Infliximab Treatment of Rheumatoid Arthritis and Crohn's Disease. Annals of Pharmacotherapy, 2003, 37, 1256-1265.	1.9	86
246	Meta-Analysis of Basiliximab for Immunoprophylaxis in Renal Transplantation. BioDrugs, 2003, 17, 271-279.	4.6	34
247	A Case for Rimantadine to Be Marketed in Canada for Prophylaxis of Influenza a Virus Infection. Canadian Respiratory Journal, 2003, 10, 381-388.	1.6	7
248	Influence of Standardized Orders on Postoperative Nausea and Vomiting after Gynecologic Surgery. Annals of Pharmacotherapy, 2002, 36, 210-217.	1.9	2
249	Quality-of-Life Assessment in an Outpatient Parenteral Antibiotic Program. Annals of Pharmacotherapy, 2002, 36, 1851-1855.	1.9	52
250	Practical pharmacogenetics: the cost effectiveness of screening for thiopurine s-methyltransferase polymorphisms in patients with rheumatological conditions treated with azathioprine. Journal of Rheumatology, 2002, 29, 2507-12.	2.0	105
251	Cost-Utility Analysis of Tissue Plasminogen Activator Therapy for Acute Ischaemic Stroke. Pharmacoeconomics, 2001, 19, 927-936.	3.3	64
252	The effectiveness and toxicity of cyclosporin A in rheumatoid arthritis: longitudinal analysis of a population-based registry. Arthritis and Rheumatism, 2001, 45, 240-245.	6.7	25

#	Article	IF	CITATIONS
253	Meta-Analysis of Proton Pump Inhibitors in Treatment of Bleeding Peptic Ulcers. Annals of Pharmacotherapy, 2001, 35, 1528-1534.	1.9	55
254	A New Ciprofloxacin Stepdown Program in the Treatment of High-Risk Febrile Neutropenia: A Clinical and Economic Analysis. Pharmacotherapy, 2000, 20, 931-940.	2.6	20
255	5-HT3 receptor antagonistsvs traditional agents for the prophylaxis of postoperative nausea and vomiting. Canadian Journal of Anaesthesia, 2000, 47, 1008-1018.	1.6	88
256	Outpatient Intravenous Antibiotic Therapy: The Vancouver Hospital experience. Canadian Journal of Infectious Diseases & Medical Microbiology, 2000, 11, 11A-14A.	0.3	1
257	A Cost-effectiveness Analysis of Pneumococcal Vaccination in Street-involved, HIV-infected Patients. Canadian Journal of Public Health, 2000, 91, 334-339.	2.3	10
258	Economic Impact of Standardized Orders for Antimicrobial Prophylaxis Program. Annals of Pharmacotherapy, 2000, 34, 154-160.	1.9	14
259	Cost Analysis of an Adult Outpatient Parenteral Antibiotic Therapy (OPAT) Programme. Pharmacoeconomics, 2000, 18, 451-457.	3.3	79
260	Cost-Effectiveness Analysis of Enoxaparin versus Unfractionated Heparin for Acute Coronary Syndromes. Pharmacoeconomics, 1999, 16, 533-542.	3.3	22
261	Cost-effectiveness of prophylactic dolasétron or droperidolvs rescue therapy in the prevention of PONV in ambulatory gynecologic surgery. Canadian Journal of Anaesthesia, 1999, 46, 536-543.	1.6	48
262	Cost-Minimization Analysis of Piperacillin/Tazobactam versus Imipenem/Cilastatin for the Treatment of Serious Infections: A Canadian Hospital Perspective. Annals of Pharmacotherapy, 1999, 33, 156-162.	1.9	7
263	Systematic Review of the Treatment of Early Lyme Disease. Drugs, 1999, 57, 157-173.	10.9	31
264	Chlamydia trachomatis in Adolescents and Adults. Pharmacoeconomics, 1998, 13, 191-222.	3.3	8
265	Cost-Effectiveness Analysis of Abciximab: A Canadian Hospital Perspective. Annals of Pharmacotherapy, 1998, 32, 536-542.	1.9	11
266	Tracking and reporting drug expenditures. American Journal of Health-System Pharmacy, 1997, 54, 2302-2306.	1.0	0
267	Cost Effectiveness Analysis of Azithromycin and Doxycycline forChlamydia TrachomatisInfection in Women: A Canadian Perspective. Canadian Journal of Infectious Diseases & Medical Microbiology, 1997, 8, 202-208.	0.3	4
268	Ampicillin-Induced Maculopapular versus Urticarial Rash. Annals of Pharmacotherapy, 1996, 30, 401-402.	1.9	0
269	Comment: cost of rhDNase in cystic fibrosis. Annals of Pharmacotherapy, 1995, 29, 1050-1051.	1.9	2